|Bid||173.64 x 800|
|Ask||173.81 x 900|
|Day's Range||172.65 - 174.62|
|52 Week Range||114.27 - 190.36|
|Beta (3Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019|
|Forward Dividend & Yield||2.96 (1.74%)|
|1y Target Est||183.40|
A landmark trial over the U.S. opioid epidemic is on track to begin on Monday after drug companies and local governments failed to agree on a settlement on Friday that had been expected to be valued at around $50 billion. Top executives of the largest U.S. drug distributors and drugmaker Teva Pharmaceutical Industries Ltd left a Cleveland courthouse on Friday and lawyers for states and thousands of local governments said there was no agreement. Paul Hanly, a lawyer for local governments that brought the bulk of the thousands of lawsuits stemming from the addiction crisis, said his team "fully expect" a trial to begin Monday.
FDA approves Lilly's (LLY) lasmiditan oral tablets to treat acute migraine. J&J (JNJ) beats earnings and sales estimates in Q3
From the start of the sprawling U.S. litigation seeking to hold drugmakers and distributors liable for the country's opioid epidemic, Judge Dan Polster has made one thing clear: he never wanted a trial. On Friday, Polster will make his most dramatic bid yet to avoid a landmark trial that is scheduled to start on Monday. The federal judge has summoned the top executives from several large healthcare companies to his Cleveland court to try to hammer out a settlement that could be worth around $50 billion.
DUBLIN , Oct. 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it will release third quarter 2019 financial results on Tuesday, November 5, 2019 , prior to the open of U.S. financial markets. ...
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
Democratic candidates like Kamala Harris and Amy Klobuchar criticized big pharma companies for their role in the opioid crisis.
Allergan plc (AGN) (the "Company" or "Allergan") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Allergan by AbbVie Inc ("AbbVie"). As described below, more than 99 percent of the votes cast at both a special court-ordered meeting of shareholders (the "Court Meeting") and at an extraordinary general meeting of shareholders (the "EGM") were in favor of the transaction, representing (in each case) approximately 68.6 percent of the shares outstanding and eligible to be voted at each of the Allergan shareholder meetings held on October 14, 2019 in Dublin, Ireland. "On behalf of Allergan's Board of Directors and executive team, I would like to thank our shareholders for their overwhelming support of the proposed combination with AbbVie," said Brent Saunders, Chairman and CEO of Allergan.
DUBLIN, Oct. 11, 2019 /PRNewswire/ -- Allergan plc, (AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology and Molecular Partners (MOLN.SW), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced two-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with neovascular (wet) age-related macular degeneration (nAMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.
DUBLIN, Oct. 10, 2019 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced a national education campaign called My Glaucoma. The campaign is designed to help people understand the burden of living with glaucoma and empower those with the disease and their caregivers to feel comfortable speaking with their doctor about a treatment regimen that fits their lifestyle. The resources available on www.MyGlaucoma.com are supported by a new survey of patients living with glaucoma and eye doctors, conducted in collaboration with Glaucoma Research Foundation (GRF), that found more than 75 percent of patients worry about vision loss because of the disease, but nearly half consider glaucoma to be only somewhat or not serious.
- A Trifecta of Relief Formulated with HydroCell™ Technology Offers New Artificial Tear Options for Patients Suffering from Eye Dryness - DUBLIN , Oct. 7, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), ...
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
Pharma companies Allergan, Bristol-Myers Squibb and Zoetis could top the Street's third-quarter earnings expectations, an analyst said Thursday. But he only expects Zoetis sales to beat.
Chardan Heathcare Acquisition Corp. (CHAC) related to its combination with BiomX Ltd. Pursuant to the terms of the Merger Agreement, BiomX's securityholders will receive an aggregate of 16,625,000 Chardan shares. As a result of the Proposed Transaction, Chardan's public stockholders will only own approximately 20% of Chardan's stock. Click here for more information: https://www.monteverdelaw.com/case/chardan-healthcare-acquisition-corp. It is free and there is no cost or obligation to you. Restoration Robotics, Inc (HAIR) related to its combination with Venus Concept Ltd. Pursuant to the terms of the Merger Agreement, each share of Venus Concept will be converted into the right to receive 8.6506 shares of Restoration Robotics common stock.
AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?
- Presentations include a late-breaking Abicipar abstract and topline Phase 3 results of Bimatoprost SR - DUBLIN , Oct. 3, 2019 /PRNewswire/ -- Allergan plc, (NYSE: AGN), a leading global pharmaceutical ...
Johnson & Johnson stock bounded higher Wednesday after the Dow Jones pharmaceutical company settled claims out of Ohio that its misleading marketing led to two counties' opioid crises.
Short interest in domestic equities, mutual funds and ETFs has risen to $905 billion this year, and the Health Care sector has seen the greatest increase in short exposure since the start of the year.